Cell-cycle dysregulation and anticancer therapy

被引:286
作者
Stewart, ZA
Westfall, MD
Pietenpol, JA
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
关键词
D O I
10.1016/S0165-6147(03)00026-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cell-cycle dysregulation is a hallmark of tumor cells. The ability of normal cells to undergo cell-cycle arrest after damage to DNA is crucial for the maintenance of genomic integrity. The biochemical pathways that stop the cell cycle in response to cellular stressors are called checkpoints. Defective checkpoint function results in genetic modifications that contribute to tumorigenesis. The regulation of checkpoint signaling also has important clinical implications because the abrogation of checkpoint function can alter the sensitivity of tumor cells to chemotherapeutics. Here, we provide an overview of the mechanisms that regulate the cell cycle, current anticancer therapies that target checkpoint signaling pathways, and strategies for the development of novel chemotherapeutic agents.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 73 条
[51]  
Roberge M, 1998, CANCER RES, V58, P5701
[52]   A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors [J].
Saito, A ;
Yamashita, T ;
Mariko, Y ;
Nosaka, Y ;
Tsuchiya, K ;
Ando, T ;
Suzuki, T ;
Tsuruo, T ;
Nakanishi, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4592-4597
[53]   Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine) [J].
Sato, S ;
Fujita, N ;
Tsuruo, T .
ONCOGENE, 2002, 21 (11) :1727-1738
[54]   A gene expression database for the molecular pharmacology of cancer [J].
Scherf, U ;
Ross, DT ;
Waltham, M ;
Smith, LH ;
Lee, JK ;
Tanabe, L ;
Kohn, KW ;
Reinhold, WC ;
Myers, TG ;
Andrews, DT ;
Scudiero, DA ;
Eisen, MB ;
Sausville, EA ;
Pommier, Y ;
Botstein, D ;
Brown, PO ;
Weinstein, JN .
NATURE GENETICS, 2000, 24 (03) :236-244
[55]   Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein [J].
Schnier, JB ;
Kaur, G ;
Kaiser, A ;
Stinson, SF ;
Sausville, EA ;
Gardner, J ;
Nishi, K ;
Bradbury, EM ;
Senderowicz, AM .
FEBS LETTERS, 1999, 454 (1-2) :100-104
[56]   Preclinical and clinical development of cyclin-dependent kinase modulators [J].
Senderowicz, AM ;
Sausville, EA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (05) :376-387
[57]   The physiology of p16INK4A-mediated G1 proliferative arrest [J].
Shapiro, GI ;
Edwards, CD ;
Rollins, BJ .
CELL BIOCHEMISTRY AND BIOPHYSICS, 2000, 33 (02) :189-197
[58]   CDK inhibitors:: positive and negative regulators of G1-phase progression [J].
Sherr, CJ ;
Roberts, JM .
GENES & DEVELOPMENT, 1999, 13 (12) :1501-1512
[59]   PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization [J].
Shin, I ;
Yakes, FM ;
Rojo, F ;
Shin, NY ;
Bakin, AV ;
Baselga, J ;
Arteaga, CL .
NATURE MEDICINE, 2002, 8 (10) :1145-1152
[60]  
Simon JA, 2000, CANCER RES, V60, P328